Anidulafungin: A drug evaluation of a new echinocandin

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 13, 2008, Pages 2339-2348

  Joseph, Jomy M ^a   Kim, Rose ^b   Reboli, Annette C ^b  

^a UNIVERSITY OF THE SCIENCES   (United States)

^b Department of Anesthesiology   (United States)

Author keywords

Anidulafungin; Antifungals; Candidemia; Echinocandins; Invasive candidiasis

Indexed keywords

ANIDULAFUNGIN; CARBAMAZEPINE; CASPOFUNGIN; CYCLOSPORIN; CYCLOSPORIN A; DEXAMETHASONE; ECHINOCANDIN; EFAVIRENZ; FLUCONAZOLE; METRONIDAZOLE; MICAFUNGIN; NEVIRAPINE; PHENYTOIN; PLACEBO; RIFAMPICIN; TACROLIMUS; VORICONAZOLE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANDIDEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DOSE KIDNEY FUNCTION RELATION; DOSE LIVER FUNCTION RELATION; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXCRETION; DRUG FEVER; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME DEFECT; ESOPHAGUS CANDIDIASIS; FETOTOXICITY; FLUSHING; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; HYPOKALEMIA; HYPOTENSION; IN VITRO STUDY; INVASIVE CANDIDIASIS; KIDNEY FAILURE; LEUKOPENIA; LIVER FAILURE; LOADING DRUG DOSE; LUNG ASPERGILLOSIS; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NAUSEA; NEUTROPENIA; NONHUMAN; OROPHARYNX CANDIDIASIS; PHARMACODYNAMICS; PHLEBITIS; PRURITUS; RASH; RECOMMENDED DRUG DOSE; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; TERATOGENICITY; TRANSAMINITIS; VOMITING;

ANTIBIOTICS, ANTIFUNGAL; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; ESOPHAGUS; FUNGEMIA; HUMANS; MYCOSES; OROPHARYNX;

EID: 52249114238     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.13.2339     Document Type: Article

References (55)

1. McNeil MM, Nash SL, Hajjeh RA, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 2001;33(5):641-7
2. Edmond MB, Wallace SE, McClish DK, et al. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999;29(2):239-44
3. Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39(3):309-17
4. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998;26(4):781-803
5. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004;38(2):161-89
6. Anidulafungin (Eraxis®) Prescribing Information. Pfizer® 2007.
7. United States Food and Drug Administration. Washington DC. FDA Approved Drug Products. Available from: http://www.fda.gov [Last accessed 3 March 2008]
8. European Medicines Agency. London, United Kingdom. Available from: http://www.emea.europa.eu. [Last accessed 11 March 2008]
9. Wagner C, Graninger W, Presterl E, Joukhadar C. The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications. Pharmacology 2006;78(4):161-77
10. Eschenauer G, DePestel DD, Carver PL. Comparison of echinocandin antifungals. Ther Clin Risk Manag 2007;3(1):71-97
11. Hector RF. Compounds active against cell walls of medically important fungi. Clin Microbiol Rev 1993;6(1):1-21
12. Bowman JC, Hicks PS, Kurtz MB, et al. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob Agents Chemother 2002;46(9):3001-12
13. Kurtz MB, Heath IB, Marrinan J, et al. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase. Antimicrob Agents Chemother 1994;38(7):1480-9
14. Roling EE, Klepser ME, Wasson A, et al. Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Cryptococcus neoformans via time-kill methods. Diagn Microbiol Infect Dis 2002;43(1):13-7
15. Pfaller MA, Diekema DJ, Gibbs DL, et al. Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J Clin Microbiol 2008;46(3):842-9
16. Arikan S, Yurdakul P, Hascelik G. Comparison of two methods and three end points in determination of in vitro activity of micafungin against Aspergillus spp. Antimicrob Agents Chemother 2003;47(8):2640-3
17. Watabe E, Nakai T, Matsumoto S, et al. Killing activity of micafungin against Aspergillus fumigatus hyphae assessed by specific fluorescent staining for cell viability. Antimicrob Agents Chemother 2003;47(6):1995-8
18. Antachopoulos; C, Meletiadis J, Sein T, et al. Comparative in vitro pbarmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. Antimicrob Agents Chemother 2008;52(1):321-8
19. Ostrosky-Zeichner L, Rex JH, Pappas PG, et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003;47(10):3149-54
20. Pfaller MA, Boyken L, Hollis RJ, et al. In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J Clin Microbiol 2005;43(11):5425-7
21. Oakley KL, Moore CB, Denning DW. In vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp. Antimicrob Agents Chemother 1998;42(10):2726-30
22. Serrano Mdel C, Valverde-Conde A, Chavez MM, et al. In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366)and amphotericin B against aspergillus spp. Diagn Microbiol Infect Dis 2003;45(2):131-5
23. Zhanel GG, Karlowsky JA, Harding GA, et al. In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species. Antimicrob Agents Chemother 1997;41(4):863-5
24. Philip A, Odabasi Z, Rodriguez J, et al. In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp. Antimicrob Agents Chemother 2005;49(8):3572-4
25. Park S, Kelly R, Kahn JN, et al. Specific substitutions in the echinocandin target Fks 1 p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother 2005;49(8):3264-73
26. Laverdiere M, Lalonde RG, Bard JG, et al. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother 2006;57(4):705-8
27. Moudgal V, Little T, Boikov D, Vazquez JA. Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother 2005;49(2):767-9
28. Ali A, Vasquez G, Vager D, et al. Pharmacodynamics of echinocandins against Candida spp, including strains with reduced susceptibility to micafungin and caspofungin while retaining anidulafungin activity [abstract M-538]. Presented at 47th Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), 2007; Chicago, IL
29. Dowell JA, Knebel W, Ludden T, et al. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J Clin Pharmacol 2004;44(6):590-8
30. Benjamin DK Jr, Driscoll T, Seibel NL, et al. Safety and pharmacokinetics of intravenous anidulafungin in children with neurropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother 2006;50(2):632-8
31. Dowell JA, Stogniew M, Krause D, Damle B. Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment. J Clin Pharmacol 2007;47(4):461-70
32. Krause DS, Simjee AE, van Rensburg C, et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 2004;39(6):770-5
33. Dowell JA, Schranz J, Baruch A, Foster G. Safety and pharmacokinctics of coadministered voriconazole and anidulafungin. J Clin Pharmacol 2005;45(12):1373-82
34. Dowell JA, Stogniew M, Krause D, et al. Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine. J Clin Pharmacol 2005;45(2):227-33
35. Louie A, Deziel M, Liu W, et al. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob Agents Chemother 2005;49(12):5058-68
36. Petraitiene R, Petraitis V, Groll AH, et al. Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits. Antimicrob Agents Chemother 1999;43(9):2148-55
37. Theuretzbacher U. Pharmacokinetics/pharmacodynamics of echinocandins. Eur J Clin Microbiol Infect Dis 2004;23(11):805-12
38. Wiederhold NP, Kontoyiannis DP, Chi J, et al. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis 2004;190(8):1464-71
39. Groll AH, Mickiene D, Petraitiene R, et al. Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob Agents Chemother 2001;45(10):2845-55
40. Gumbo T, Drusano GL, Liu W, et al. Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis. Antimicrob Agents Chemother 2006;50(11):3695-700
41. Andes D, Marchillo K. In vivo pharmacodynamic characterization of a new echinocandin, anidulafungin, against Candida albicans and Candida glabrata in the neutropenic murine disseminated candidiasis model. Antimicrob Agents Chemother 2008;52(2):539-50
42. Kelley K, Chapman S, Cleary JD. Digestion of echinocandins [abstract M-366]. Presented at 46th Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC); 2006; San Francisco, CA
43. de Wet N, Llanos-Cuentas A, Suleiman J, et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 2004;39(6):842-9
44. Villanueva A, Gotuzzo E, Arathoon EG, et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002;113(4):294-9
45. Vazquez JA, Schranz JA, Clark K, et al. A phase 2, open-label study of the safety and efficacy of intravenous anidulafungin as a treatment for azole refractory mucosal candidiasis. J Acquir Immune Defic Syndr 2008;48(3):304-9
46. Krause DS, Reinhardt J, Vazquez JA, et al. Phase 2, randomized, dose ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antinticrob Agents Chemother 2004;48(6):2021-4
47. Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007;356(24):2472-82
48. Brielmaier BD, Casabar E, Kurtzeborn CM, et al. Early clinical experience with anidulafungin at a large tertiary care medical center. Pharmacotherapy 2008;28(1):64-73
49. Hurren JR, Davis SL, Vazquez JA. What is the risk of disulfram-like reaction during anidulafungin and metronidazole administration? [abstract K-2158]. Presented at 47th Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC); 2007; Chicago, IL
50. Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007;45(7):883-93
51. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347(25):2020-9
52. Caspofungin (Cancidas®) Prescribing Information. Merck & Co., Inc. 2005.
53. Micafungin (Mycamine®) Prescribing Information. Astellas Pharma US, Inc. 2008.
54. Sandhu P, Lee W, Xu X, et al. Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab Dispos 2005;33(5):676-82
55. Odds FC, Brown AJ, Gow NA. Trends Microbiol 2003;11(6):272-9